Company news
Lilly will pay $62 million to 32 states investigating the company over its marketing of Zyprexa, an antipsychotic drug indicated for schizophrenia and some forms of bipolar disorder.
Lilly will pay $62 million to 32 states investigating the company over its marketing of Zyprexa, an antipsychotic drug indicated for schizophrenia and some forms of bipolar disorder.
Get the most out of
Register for free and enjoy unlimited access to: